Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. is dated July 21, 2026. The report serves primarily to incorporate by reference a press release (Exhibit 99.1) into the company's existing registration statements on Form F-3 and Form S-8. The filing identifies Jonathan Dickinson as the Chief Executive Officer.
Key Financial Metrics
The provided filing text does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior periods. The document focuses on regulatory incorporation rather than financial performance updates.
Guidance, Outlook, and Risks
While the filing incorporates a press release by reference, the text explicitly excludes the quotation from the CEO, references to live webcasts, and related links. Consequently, no specific guidance, management commentary, risks, or unusual items are detailed within the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated July 21, 2026) directly, as the financial and operational details are contained therein but excluded from the summary text of this Form 6-K.
- Verify the status of the registration statements on Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031) to understand the context of the incorporation by reference.
- Confirm the content of the CEO's statement and any webcast materials, as these were specifically omitted from the text of this filing.